ArticleEmerging microbes & infections2023
CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection.
Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- CRIPSR-Cas for hepatitis virus: a systematic review and meta-analysis of diagnostic test accuracy studies.Frontiers in microbiology · 2025Pooled it
- Beyond DNA editing: how Cas13 redefined programmable RNA manipulation and what still limits its therapeutic promise.Nucleic acids research · 2026Review
- Validation of a Qualitative Detection Method for Influenza A Virus RNA Based on the RT-RPA-CRISPR/Cas13a System.Current microbiology · 2026Article
- CRISPR-Cas13a/Cas12a Assisted Dual Portable and Visualized HDV and HBV Detection.Journal of medical virology · 2026Article
- Challenges in accurate HDV RNA quantification: inter-assay variability and the impact of thermal shock.Journal of clinical microbiology · 2026Article
- A CRISPR-Cas13a-based two-step assay combined with lateral flow strips for rapid detection of Epstein-Barr virus.Frontiers in microbiology · 2026Article
- Development of a rapid, sensitive and visual reverse transcription recombinase-aided amplification coupled with lateral flow dipstick assay for influenza B virus detection.Frontiers in microbiology · 2026Article
- CRISPR-based point-of-care diagnostics for viral hepatitis: from molecular design to clinical implementation.Frontiers in bioengineering and biotechnology · 2026Review
- Disrupting Viral Persistence: CRISPR/Cas9-Based Strategies for Hepatitis B and C Treatment, and Challenges.Journal of cellular and molecular medicine · 2026Review
- CRISPR-based diagnostics for infectious diseases: mechanisms, advancements and clinical transformation prospects.Frontiers in cellular and infection microbiology · 2026Review
- CRISPR-assisted MoSMikrochimica acta · 2025Article
- CRISPR/Cas13-Based Anti-RNA Viral Approaches.Genes · 2025Review
- Review
- One-Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point-of-Care Testing.Journal of medical virology · 2024Article
- Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses.Emerging microbes & infections · 2024Article
- Realm of hepatitis E: Challenges and opportunities.World journal of experimental medicine · 2024Article
- Current Trends in RNA Virus Detection via Nucleic Acid Isothermal Amplification-Based Platforms.Biosensors · 2024Review
- Combination of nucleic acid amplification and CRISPR/Cas technology in pathogen detection.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHepatitis delta virus (HDV) infection accelerates the progression of chronic hepatitis B virus (HBV) infection, posing a large economic and health burden to patients. At present, there remains a lack of accurate and portable detection methods for HDV RNA. Here, we aim to establish a convenient, rapid, highly sensitive and specific method to detect HDV RNA using CRISPR-Cas13a technology.
methodsWe established fluorescence (F) and lateral flow strip (L) assays based on CRISPR-Cas13a combined with RT-PCR and RT-RAA for HDV RNA detection, respectively. we conducted a cohort study of 144 patients with HDV-IgG positive to evaluate the CRISPR-Cas13a diagnostic performance for identifying HDV in clinical samples, compared to RT-qPCR and RT-ddPCR.
resultsFor synthetic HDV RNA plasmids, the sensitivity of RT-PCR-CRISPR-based fluorescence assays was 1 copy/μL, higher than that of RT-qPCR (10 copies/μL) and RT-ddPCR (10 copies/μL); for HDV RNA-positive samples, the sensitivity of RT-RAA-CRISPR-based fluorescence and lateral flow strip assays was 10 copies/μL, as low as that of RT-qPCR and RT-ddPCR, and the assay took only approximately 85 min. Additionally, the positivity rates of anti-HDV IgG-positive samples detected by the RT-qPCR, RT-ddPCR, RT-PCR-CRISPR fluorescence and RT-RAA-CRISPR lateral flow strip methods were 66.7% (96/144), 76.4% (110/144), 81.9% (118/144), and 72.2% (104/144), respectively.
conclusionsWe developed a highly sensitive and specific, as well as a portable and easy CRISPR-based assay for the detection of HDV RNA, which could be a prospective measure for monitoring the development of HDV infection and evaluating the therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.